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In 1994, The American Journal of Pathology pub-
lished a key article reporting that hypoxic retina pro-
duces vascular endothelial growth factor (VEGF), sug-
gesting a role for VEGF in ocular neovascularization.
Subsequent developments in anti-VEGF treatment for
neovascular eye disease have improved visual out-
comes and changed the standard of care in retinal
medicine and ophthalmology. (Am J Pathol 2012, 181:
376–379; http://dx.doi.org/10.1016/j.ajpath.2012.06.006)
This story starts in the early 1970s with the proposal by Judah
Folkman1 that tumor growth and progression is dependent on
the ability of the tumor to recruit and support formation of a
vasculature. This concept prompted a significant effort to pu-
rify a tumor-derived angiogenic factor, which led to the identi-
fication and purification of acidic and basic fibroblast growth
factors (FGF-1 and FGF-2, respectively). However, the very
wide distribution of the two growth factors, the fact that both
molecules lack a conventional signal sequence, and the sub-
sequent finding of very modest phenotypes in mice lacking
either FGF-1 or FGF-2 tempered enthusiasm regarding their
possible role in tumor angiogenesis.
The publication in 1989 of two back-to-back articles in Sci-
ence2,3 began a new phase in this chronicle, one that culmi-
nated in the relatively recent development of antiangiogenic
therapies. One article reported the isolation of an endothelial
mitogen from pituitary follicular cells, which the authors termed
vascular endothelial cell growth factor (VEGF).2 The other ar-
ticle described a tumor-derived factor, termed vascular per-
meability factor (VPF), thatwaspurifiedon thebasis of its ability
to induced vascular permeability.3 Subsequent cloning and
sequencing of the genes encoding these factors led to the
realization that the two factors are identical. (Under current
nomenclature, the recommended name is vascular endothe-
lial growth factor, with vascular permeability factor as an alter-
native.) To date, antiangiogenesis has had the most dramatic
effect in the treatment of neovascular diseases of the eye,
which is addressed here in this commentary.
376VEGF and Neovascular Eye Disease
It had long been postulated that areas of ischemic retina,
which characterize a number of ocular pathologies (most no-
tably diabetic retinopathy and retinopathy of prematurity)
would produce an agent, as yet unknown, that stimulates the
growth of new blood vessels. In 1956 George Wise wrote,
“Pure retinal neovascularization is directly related to a tissue
state of relative retinal anoxia. Under such circumstances, an
unknown factor x develops in this tissue and stimulates new
vessel formation, primarily from the capillaries and veins.”4
Early efforts to identify this factor x led to the isolation of acidic
and basic fibroblast growth factors from retina.5 At about the
same time, however, two studies using the rapidly growing
and highly vascularized glioblastoma tumor model demon-
strated that the expression of VEGF is associated with new
vessel growth and is driven by hypoxia.6,7 These findings,
togetherwith the fact that VEGFnot only acts as an angiogenic
factor but is also able to induce permeability, made VEGF
particularly attractive as a candidate for the long-sought-after
factor x.
A key demonstration that hypoxic retina produces VEGF
waspublished inTheAmerican Journal of Pathology in 1994.8 In
that study, the retinas of nonhuman primates were rendered
ischemic by laser photocoagulation of the veins. This resulted
in neovascularization of the iris (reminiscent of the rubeosis
iridis sometimes associated with proliferative diabetic retinop-
athy), suggesting the presence of a diffusiblemolecule. Levels
of VEGF mRNA and protein were shown to be elevated in a
manner that was spatially and temporally consistent with a role
for VEGF in the growth of new vessels. In that same year, there
was a report of elevated levels of VEGF in ocular fluids from
patients with active neovascular ocular disease but not in oc-
ular fluids from patients with no vessel growth.9 Together,
these articles provided intriguing circumstantial evidence of a
role for VEGF in ocular neovascularization.
Evidence in support of a direct role for VEGF in new vessel
growth in the eye came from studies using anti-VEGF anti-
Supported by K12-EY16335 (L.A.K.) and EY05318 and EY015435
(P.A.D.).
Accepted for publication June 25, 2012.
Address reprint requests to Patricia A. D’Amore, Ph.D., Schepens Eye
Institute and Harvard Medical School, 20 Staniford St., Boston, MA 02114.
E-mail: patricia.damore@schepens.harvard.edu.
ASIP Centennial Commentary 377
AJP August 2012, Vol. 181, No. 2sera,10 soluble VEGF receptor,11 anti-VEGF aptamers,12 and
VEGFR1-neutralizing antisera.13 Evidence that VEGF is not
only necessary but sufficient was provided by the demonstra-
tion that injection of VEGF into the eye of a nonhuman primate
stimulated the growth and permeability of new vessels on the
retina, and also induced neovascular glaucoma.14
Anti-VEGF Therapy
Neovascular Age-Related Macular Degeneration
The first treatment developed using a VEGF-neutralizing strat-
egy was bevacizumab (Avastin), a humanized anti-VEGF an-
tibody designed to block all VEGF isoforms. In 1997, Genen-
tech (South San Francisco, CA) initiated phase 1 trials of
bevacizumab for the treatment of cancer and established that
it had minimal toxicity.15 A phase 2 trial comparing bevaci-
zumab combined with fluorouracil and leucovorin, against a
control arm of fluorouracil and leucovorin alone, revealed a
longer median survival time in the combined bevacizumab
regimen (21.5 months, compared with 13.8 months for the
control).16 A phase 3 trial indicated that the addition of bevaci-
zumab to control groups receiving a regimen of irinotecan,
fluorouracil, and leucovorin increasedmedian survival times.17
Taken together, these results led to approval by the U.S. Food
and Drug Administration (FDA) on February 26, 2004, of bev-
acizumab for the treatment of coloncancer in combinationwith
chemotherapy.
Concomitant with the development of anti-VEGF therapies
for cancer, VEGF was found to play a pivotal role in neovas-
cular age-relatedmacular degeneration (NVAMD).NVAMD,or
wet AMD, is the leading cause of blindness in the elderly
population. One of the first anti-VEGF therapies for NVAMD
was pegaptanib (Macugen), an RNA aptamer that binds and
neutralizes VEGF165 (and likely also VEGF188, although this
has not been substantiated). This therapy, developed by
Eyetech Pharmaceuticals (New York, NY), was shown in two
large phase 2 and 3 trials to decrease the progressive loss of
vision associated with NVAMD.18 Pegaptanib was approved
by the FDA on December 17, 2004, for the treatment of
NVAMD, making it the first antiangiogenic therapeutic ap-
proved for ocular neovascularization.
After approval of bevacizumab for cancer therapy and
given the suspected role of VEGF in NVAMD, systemic intra-
venous bevacizumab began to be administered to treat
NVAMD, as an off-label use. A small open-label, single-center
uncontrolled study showed significant improvement in visual
acuity, retinal thickness on optical coherence tomography,
and angiographic outcomes; after 12 weeks of therapy, the
median and mean visual acuity improved by 8 and 12 letters,
respectively.19 Soon after, ophthalmologists began injecting
bevacizumab directly into the vitreous cavity as an off-label
use in the treatment of NVAMD. Intravitreal injection of bevaci-
zumab was found to be effective in the treatment of NVAMD,
with minimal systemic adverse effects, which led to the first
studies to demonstrate an improvement in visual function in
patients with NVAMD.20
It was initially expected that bevacizumab would not diffuse
through the retina efficiently enough to reach the choroid,
prompting Genentech to generate an alternative molecule. A
truncated and modified variant of bevacizumab, known asranibizumab (Lucentis), was created by alteration of the com-
plementarydomain regionof bevacizumab, followedbyaffinity
selection by phage display.21 Subsequent phase 3 clinical
studies determined ranibizumab to be an effective treatment
for NVAMD, with a significant improvement in vision. Contrary
to the original understanding, full-length anti-VEGF antibody
does, in fact, diffuse well in diseased retinas. First, the earlier
studies examining antibody diffusibility were not, in fact, con-
ducted with anti-VEGF antibodies, but rather with humanized
rhuMAb HER2 antibody, which may bind specifically in the
retina.22 Second, the fact that the diseased retina is not intact
likely facilitates diffusion of the antibodies.
The effectiveness of ranibizumab was determined by two
pivotal trials: the Minimally Classic/Occult Trial of the Anti-
VEGF Antibody Ranibizumab in the Treatment of Neovascular
Age-Related Macular Degeneration (MARINA) and the Anti-
VEGF Antibody for the Treatment of Predominantly Classic
Choroidal Neovascularization in Age-Related Macular Degen-
eration (ANCHOR). MARINA and ANCHOR were the first
phase 3 trials to show improvement in visual outcomes for all
forms of choroidal neovascularization in NVAMD.23,24 Based
on this evidence, ranibizumab was approved by the FDA on
June 30, 2006, for the treatment of NVAMD.
Recently, bevacizumab and ranibizumab were compared
and found to have equivalent visual outcomes. The Compari-
son of Age-Related Macular Degeneration Treatment Trials
(CATT) revealed equivalent effects on visual acuity after 1 year
of monthly administration of either bevacizumab or ranibi-
zumab.25 Similarly, the two drugs were equivalent when given
as needed. The results suggest that these two closely related
molecules have equivalent clinical efficacy (as might be ex-
pected, given their similar modes of action). The current stan-
dard of care in the treatment of NVAMD is the use of anti-VEGF
antibodies.
Another anti-VEGF strategy, developed by Regeneron
Pharmaceuticals (Tarrytown, NY), consists of a chimeric fusion
protein comprising the second immunoglobulin domain of
VEGF receptor 1, the third immunoglobulin domain of VEGF
receptor 2, and the Fc portion of human IgG1.26 This so-called
VEGF-trap (aflibercept) functions as a decoy receptor to se-
quester VEGF, thereby blocking its biological effects. Afliber-
ceptwasdeveloped to improve thepharmacokinetics of VEGF
binding. Aflibercept exhibits a binding affinity near 0.5 pmol/L,
compared with 50 pmol/L for ranibizumab or bevacizumab,
which represents a 100-fold increase in binding affinity. In
addition, the intravitreal half-life of aflibercept is 4.8 days, com-
pared with 3.2 days and 5.6 days for ranibizumab and bev-
acizumab, respectively.27 The improved pharmacokinetics of
aflibercept is thought to decrease the frequency of dosing in
patients, with similar efficacy as anti-VEGFantibodies. Phase 3
results from the VIEW trials (VEGF Trap: Investigation of Effi-
cacy andSafety inWet AMD) revealed that 2mgof aflibercept
dosed every 2 months was not inferior to ranibizumab dosed
monthly. Basedon these studies, afliberceptwas approvedby
the FDA on November 18, 2011.
Diabetic Retinopathy
In addition to its role in NVAMD, VEGF plays a critical role in
diabetic retinopathy and contributes to the development of
diabetic macular edema (DME). DME is the leading cause of
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tries. Analogous to the use of anti-VEGF treatment in NVAMD,
bevacizumab, ranibizumab, and aflibercept have all been
shown to have some efficacy in the treatment of DME. How-
ever, given the relatively rapid improvement ofmacular edema
with anti-VEGF treatment, anti-VEGF therapy for DME is likely
mediated by modulating VEGF-induced vascular permeabil-
ity. To date, the FDA has not approved the use of any of the
anti-VEGF agents for the treatment of DME. However, ranibi-
zumab has been approved for the treatment of DME in Europe
and Australia.
The treatment of DME with bevacizumab has been evalu-
ated in a variety of trials. One of the larger trials investigated
intravitreal bevacizumab alone or in combination with intravit-
real triamcinolone versus macular laser photocoagulation.28
The results of the 2-year study showed superiority of visual
improvement in the bevacizumab-alone group at the 6-month
time point, and these findings were sustained over the 24-
month study period. Intravitreal bevacizumab demonstrated
only slight superiority in visual acuity over either intravitreal
bevacizumab combinedwith intravitreal triamcinolone ormac-
ular laser photocoagulation.
The efficacy and safety of intravitreal ranibizumabwas eval-
uated in the Ranibizumab Injection in Subjects With Clinically
Significant Macular Edema With Center Involvement Second-
ary to Diabetes Mellitus (RISE and RIDE) trials. These parallel
studies evaluatedmonthly intravitreal ranibizumab injections at
0.5 or 0.3 mg versus sham injections in the treatment of DME,
with macular laser photocoagulation available according to
protocol guidelines. These studies revealed significant im-
provement in visual acuity (in approximately 63% of patients),
decreased macular edema, decreased worsening of retinop-
athy, and increased likelihood of improvement with laser ther-
apy in the ranibizumab-treatedgroups.Asignificant proportion
of patients exhibited persistently poor vision despite resolution
of macular edema, suggesting that anti-VEGF therapy does
not restore damaged retinal tissue.Ocular safetywas similar to
that in previous ranibizumab studies.29
A phase 2 study of aflibercept for the treatment of DME
assessed different doses of aflibercept versus macular laser
photocoagulation. In general, aflibercept therapy was well tol-
erated in the eye and resulted in statistically significant visual
gains and reduction in macular thickness. One-third of the
aflibercept patients gained 15 or more letters from baseline,
compared with only 21% in the laser-treated patients. Mean
reductions in macular thickness ranged from 127.3 to 194.5
m, compared with only 67.9 m in the laser-treated group.
Retinal Vein Occlusions
VEGF neutralization has also been found to be effective in the
treatment of macular edema associated with vein occlusions.
Retinal vein occlusion is the second most common retinal
vascular disease after diabetic retinopathy. Results from the
Ranibizumab for the Treatment of Macular Edema following
Branch Retinal Vein Occlusion (BRAVO) trial found that ranibi-
zumab at doses of 0.3 and 0.5 mg resulted in a higher pro-
portion of subjects who gained 15 or more letters at the
6-month time point. Specifically, 55.2% (0.3 mg) and 61.1%
(0.5 mg) of patients in the ranibizumab groups and 28.8% in
the sham group gained 15 or more letters at 6 months. Theranibizumabgroup also had a statistically significant decrease
in retinal thickness, compared with the control group.30
Central retinal vein occlusions are also amenable to ranibi-
zumab therapy. The Ranibizumab for the Treatment of Macu-
lar EdemaafterCentral Retinal VeinOcclusionStudy (CRUISE)
trial yielded similar results. The proportion of patients who
gained 15 or more letters in visual acuity at 6 months was
46.2% (0.3mg) and47.7% (0.5mg) in the ranibizumabgroups
and 16.9% in the sham injection group. Similar to findings from
other trials, central foveal thickness as determined by optical
coherence tomographywas significantly reduced in the ranibi-
zumab groups.
Summary
Other significant findings relevant to understanding the role of
VEGF in the eye have appeared in the pages of The American
Journal of Pathology. Insight into the mechanisms of VEGF
up-regulation came from studies demonstrating that the inhi-
bition of NAD(P)H oxidase could block ischemia-induced
VEGF up-regulation.31 Consistent with a known role for VEGF
in vascular development, retinal pigment epithelial cell-derived
VEGF has been shown to play a critical role for in the formation
of the choriocapillaris,32 whereas overexpression of VEGF
leads to choroidal neovascularization.33 The fact that virtually
every adult tissue expresses VEGF in a cell type-specific fash-
ion points to a postdevelopmental role for VEGF.34,35 Consis-
tent with this idea, evidence indicates VEGF is a survival factor
and neuroprotectant for retinal neurons,36–38 observations that
have led some to raise concerns regarding chronic VEGF
neutralization in patients. One of the efforts to improve the
efficacy of anti-VEGF therapy involves the simultaneous block-
ade of PDGF-B signaling.39,40
The progress in scientific development and in treatment of
diseases caused by pathological ocular angiogenesis high-
lights the importanceof basic researchdedicated to improving
patient care. The use of anti-VEGF therapies has introduced a
paradigm shift in the treatment of a wide array of ocular dis-
eases, includingNVAMD,diabetic retinopathy, and retinal vein
occlusions. Before the development of anti-VEGF therapies,
these conditionsweremost often treatedwith a combination of
ablative and nonspecific laser treatment or were simply given
careful observation and monitoring, with a universal decline in
vision. The current use of anti-VEGF treatment has resulted in
improvement of visual outcomes and has changed the stan-
dard of care in retinal medicine and ophthalmology.
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